SLDB Material Contracts | Solid Biosciences Inc.

Solid Biosciences Inc. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

2026-08-06: Form 10-Q; Exhibit 10.1; Description Summary of Non-Employee Director Compensation Program.
2026-05-12: Form 10-Q; Exhibit 10.1; Description Summary of Non-Employee Director Compensation Program.
2026-03-19: Form 10-K; Exhibit 10.49; Description 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.49 to the Annual Report on Form 10-K filed on March 13, 2024)..
2026-03-19: Form 10-K; Exhibit 10.35; Description Employment Agreement, dated October 2, 2023, by and between Solid Biosciences Inc. and Gabriel Brooks, as amended..

Filed	Form	Exhibit	Description
2026-08-06	10-Q	10.1	Summary of Non-Employee Director Compensation Program
2026-05-12	10-Q	10.1	Summary of Non-Employee Director Compensation Program
2026-03-19	10-K	10.49	2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.49 to the Annual Report on Form 10-K filed on March 13, 2024).
2026-03-19	10-K	10.35	Employment Agreement, dated October 2, 2023, by and between Solid Biosciences Inc. and Gabriel Brooks, as amended.
2026-03-19	10-K	10.34	Employment Agreement, dated January 9, 2023, by and between Solid Biosciences Inc. and Kevin Tan, as amended.
2026-03-19	10-K	10.33	Employment Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and David Tyronne Howton, as amended.
2026-03-19	10-K	10.31	Employment Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and Alexander Cumbo, as amended.
2026-03-19	10-K	10.14	Executive Chair Agreement, effective January 1, 2022, by and between Solid Biosciences Inc. and Ian F. Smith, as amended by the First Amendment to Executive Chair Agreement, effective September 30, 2022, Second Amendment to the Executive Chair Agreement, effective January 1, 2024, Third Amendment to the Executive Chair Agreement, effective January 6, 2025 and Fourth Amendment to Executive Chair Agreement, effective January 1, 2026.
2026-03-06	8-K	10.2	Form of Registration Rights Agreement, dated March 6, 2026, by and among the Company and the other parties thereto.
2026-03-06	8-K	10.1	Form of Securities Purchase Agreement, dated March 6, 2026, by and among the Company and the other parties thereto.
2025-03-06	10-K	10.51	Form of Restricted Stock Unit Agreement under the 2024 Inducement Stock Incentive Plan. Form of Restricted Stock Unit Agreement under the 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.51 to the Annual Report on Form 10-K filed on March 13, 2024).
2025-03-06	10-K	10.50	Form of Non-Statutory Stock Option Agreement under the 2024 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 10.50 to the Annual Report on Form 10-K filed on March 13, 2024).
2025-03-06	10-K	10.14	Executive Chair Agreement, effective January 1, 2022, by and between Solid Biosciences Inc. and Ian F. Smith, as amended by the First Amendment to Executive Chair Agreement, effective September 30, 2022, Second Amendment to the Executive Chair Agreement, effective January 1, 2024, and Third Amendment to the Executive Chair Agreement, effective January 6, 2025.
2025-03-06	10-K	10.10	Summary of Non-Employee Director Compensation Program
2024-05-15	10-Q	10.2	Employment Agreement, dated January 9, 2023, by and between Solid Biosciences Inc. and Kevin Tan
2024-03-13	10-K	10.56	License Agreement, dated as of August 3, 2017, by and between Solid Biosciences, LLC and President and Fellows of Harvard College.
2024-03-13	10-K	10.55	License Agreement, dated as of June 23, 2016, by and between Solid GT, LLC and President and Fellows of Harvard College.
2024-03-13	10-K	10.54	Life Technologies Cell Line License Agreement, dated as of November 20, 2016, by and between Solid Biosciences, LLC and Life Technologies Corporation.
2024-03-13	10-K	10.53	Patent License Agreement, dated as of March 10, 2016, by and between Solid GT, LLC and the Regents of the University of Michigan.
2024-03-13	10-K	10.52	Form of Restricted Stock Unit Agreement under the 2020 Equity Incentive Plan.
2024-03-13	10-K	10.51	Form of Restricted Stock Unit Agreement under the 2024 Inducement Stock Incentive Plan.
2024-03-13	10-K	10.50	Form of Non-Statutory Stock Option Agreement under the 2024 Inducement Stock Incentive Plan.
2024-03-13	10-K	10.49	2024 Inducement Stock Incentive Plan.
2024-03-13	10-K	10.30	Amended and Restated Sales Agreement, dated March 13, 2024, by and between the Company and Jefferies LLC.
2024-03-13	10-K	10.27	Amended and Restated 2021 Employee Stock Purchase Plan.
2024-03-13	10-K	10.15	Executive Chair Agreement, effective January 1, 2022, by and between Solid Biosciences Inc. and Ian F. Smith, as amended by the First Amendment to Executive Chair Agreement, effective September 30, 2022, and Second Amendment to the Executive Chair Agreement, effective January 1, 2024
2024-03-13	10-K	10.8	License Agreement, dated as of October 15, 2015, by and between Solid GT, LLC and The Curators of the University of Missouri.
2024-03-13	10-K	10.7	Exclusive Patent License Agreement, dated as of October 16, 2015, by and between Solid GT, LLC and the University of Washington.
2024-01-08	8-K	10.2	Form of Registration Rights Agreement, dated January 8, 2024, by and among the Company and the other parties thereto.
2024-01-08	8-K	10.1	Form of Securities Purchase Agreement, dated January 8, 2024, by and among the Company and the other parties thereto.
2023-11-08	10-Q	10.1	Employment Agreement, dated October 2, 2023, by and between Solid Biosciences Inc. and Gabriel Brooks
2023-08-14	10-Q	10.2	Consulting Agreement dated as of July 14, 2023, between Solid Biosciences Inc. and PHDL Consulting LLC
2023-08-14	10-Q	10.1	Executive Transition and Separation Agreement, dated as of May 22, 2023, between Solid Biosciences Inc. and Carl Morris
2023-05-11	10-Q	10.2	Employment Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and David Tyronne Howton.
2023-03-23	10-K	10.43	Standard Exclusive License Agreement With Know-How (Agreement No. A19111), dated as of March 17, 2020, by and between AavantiBio, Inc. and University of Florida Research Foundation, Incorporated, as amended on May 25, 2021 and August 23, 2022.
2023-03-23	10-K	10.42	Standard Exclusive License Agreement With Know-How (Agreement No. A19110), dated as of March 17, 2020, by and between AavantiBio, Inc. and University of Florida Research Foundation, Incorporated, as amended on August 23, 2022.
2023-03-23	10-K	10.17	Executive Chair Agreement, effective January 1, 2022, by and between Solid Biosciences Inc. and Ian F. Smith, as amended by the First Amendment to Executive Chair Agreement, effective September 30, 2022.
2023-03-23	10-K	10.12	Summary of Non-Employee Director Compensation Program.
2022-09-30	8-K	10.9	Consulting Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and Erin Powers Brennan
2022-09-30	8-K	10.8	Executive Transition and Separation Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and Erin Powers Brennan
2022-09-30	8-K	10.7	Consulting Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and Ilan Ganot
2022-09-30	8-K	10.6	Executive Transition and Separation Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and Ilan Ganot
2022-09-30	8-K	10.5	Employment Agreement, dated September 29, 2022, by and between Solid Biosciences Inc. and Alexander Cumbo
2022-09-30	8-K	10.4	Registration Rights Agreement, dated September 29, 2022, by and among Solid Biosciences Inc. and the persons party thereto
2022-09-30	8-K	10.3	Securities Purchase Agreement, dated September 29, 2022, by and among Solid Biosciences Inc. and the persons party thereto
2022-09-30	8-K	10.2	Form of Support and Joinder Agreement
2022-09-30	8-K	10.1	Form of Parent Support Agreement
2022-08-11	10-Q	10.1	Summary of Non-Employee Director Compensation Policy.
2022-03-14	10-K	10.37	Amendment No. 1 to Sublease, dated as of December 3, 2021, by and between Solid Biosciences, LLC and Twitter, Inc.
2022-03-14	10-K	10.28	Form of Restricted Stock Unit Agreement under the 2020 Equity Incentive Plan.
2022-03-14	10-K	10.26	2020 Equity Incentive Plan, as amended by Amendment No. 1 to 2020 Stock Incentive Plan.
2022-03-14	10-K	10.25	Executive Chair Agreement, effective January 1, 2022, by and between Solid Biosciences Inc. and Ian F. Smith.
2022-03-14	10-K	10.18	Summary of Non-Employee Director Compensation Program.
2022-03-14	10-K	10.4	Employment Agreement, dated as of March 1, 2021, by and between Solid Biosciences Inc. and Erin Powers Brennan.
2022-03-14	10-K	10.3	Employment Agreement, dated as of January 25, 2019, by and between Solid Biosciences Inc. and Joel Schneider.
2021-11-03	10-Q	10.2	Sales Agreement, dated March 13, 2019, by and between the Registrant and Jefferies LLC, as amended by Amendment No. 1 to the Sales Agreement, dated August 16, 2021, by and between the Registrant and Jefferies LLC
2021-11-03	10-Q	10.1	2021 Employee Stock Purchase Plan
2021-08-16	10-Q	10.4	Form of Nonstatutory Inducement Stock Option Agreement.
2021-08-16	10-Q	10.1	Lease, dated June 15, 2021, between Solid Biosciences, Inc. and Hood Park LLC.
2021-05-14	10-Q	10.1	Consulting Agreement, dated as of January 4, 2021, by and between Solid Biosciences Inc. and Ian F. Smith.
2021-03-15	10-K	10.36	First Amendment, dated as of January 27, 2021, to the Exclusive Patent License by and between the Company and the Curators of the University of Missouri
2021-03-15	10-K	10.24	Consulting Agreement, dated as of November 19, 2020, by and between Solid Biosciences Inc. and Danforth Advisors, LLC.
2021-03-15	10-K	10.3	Employment Agreement, dated as of January 25, 2019, by and between Solid Biosciences Inc. and Jennifer Ziolkowski.
2020-12-11	8-K	10.2	Registration Rights Agreement, dated December 10, 2020, by and among the Company and the other parties thereto.
2020-12-11	8-K	10.1	Securities Purchase Agreement, dated December 10, 2020, by and among the Company and the other parties thereto.
2020-11-05	10-Q	10.4	First Amendment, dated as of October 9, 2020, to the Exclusive Patent License by and between the Company and the University of Washington.
2020-11-05	10-Q	10.3	Investor Agreement, dated as of October 22, 2020, by and between the Company and Ultragenyx Pharmaceutical Inc
2020-11-05	10-Q	10.2	Stock Purchase Agreement, dated as of October 22, 2020, by and between the Company and Ultragenyx Pharmaceutical Inc.
2020-11-05	10-Q	10.1	Collaboration and License Agreement, dated as of October 22, 2020, by and between the Company and Ultragenyx Pharmaceutical Inc.
2020-08-06	10-Q	10.5	Form of Restricted Stock Unit Agreement under the 2020 Equity Incentive Plan.
2020-08-06	10-Q	10.4	Form of Stock Option Agreement under the 2020 Equity Incentive Plan.
2020-08-06	10-Q	10.2	Consulting Agreement, dated as of June 16, 2020, by and between Solid Biosciences Inc. and Ian F. Smith
2020-08-06	10-Q	10.1	Summary of Non-Employee Director Compensation Program.
2020-05-07	10-Q	10.2	Consulting Agreement, dated as of February 1, 2020, by and between Solid Biosciences Inc. and Ian F. Smith
2020-05-07	10-Q	10.1	Summary of Non-Employee Director Compensation Program.
2020-03-12	10-K	10.27	Employment Agreement, dated as of January 25, 2019, by and between Solid Biosciences Inc. and Jorge Quiroz.
2020-03-12	10-K	10.26	Consulting Agreement, dated as of January 15, 2020 by and between Solid Biosciences Inc. and Jorge Quiroz.
2020-03-12	10-K	10.25	Consulting Agreement, dated as of January 15, 2020, by and between Solid Biosciences Inc. and Alvaro Amorrortu.
2020-03-12	10-K	10.24	Consulting Agreement, dated as of January 1, 2020, by and between Solid Biosciences Inc. and Andrey Zarur.
2019-07-26	8-K	10.3	Registration Rights Agreement, dated July 25, 2019, by and among the Company and the other parties thereto.
2019-07-26	8-K	10.2	Form of Pre-Funded Warrant to Purchase Common Stock to be issued pursuant to the Securities Purchase Agreement.
2019-07-26	8-K	10.1	Securities Purchase Agreement, dated July 25, 2019, by and among the Company and the other parties thereto.
2019-05-13	10-Q	10.1	Consulting Agreement, dated as of January 1, 2019, by and between Solid Biosciences Inc. and Andrey Zarur
2019-03-13	10-K	10.20	Summary of Non-Employee Director Compensation Program.
2019-03-13	10-K	10.8	Form of Nonqualified Stock Option Agreement under 2018 Omnibus Incentive Plan.
2019-03-13	10-K	10.7	Form of Incentive Stock Option Agreement under 2018 Omnibus Incentive Plan.
2019-03-13	10-K	10.4	Employment Agreement, dated as of January 25, 2019, by and between Solid Biosciences Inc. and Carl Morris. Ph.D.
2019-03-13	10-K	10.3	Employment Agreement, dated as of January 25, 2019, by and between Solid Biosciences Inc. and Alvaro Amorrortu
2019-03-13	10-K	10.2	Employment Agreement, dated as of January 25, 2019, by and between Solid Biosciences Inc. and Ilan Ganot.
2018-11-13	10-Q	10.1	Summary of Non-Employee Director Compensation Program
2018-08-10	10-Q	10.1	Summary of Non-Employee Director Compensation Program
2018-03-29	10-K	10.21	Lease Agreement, dated as of December 22, 2017, by and between Solid Biosciences, LLC and ARE-MA Region No. 59, LLC.
2018-03-29	10-K	10.20	Sublease, dated as of January 30, 2018, by and between Solid Biosciences, LLC and Twitter, Inc.
2018-03-29	10-K	10.7	Solid Biosciences, LLC Amended and Restated Equity Incentive Plan and form of unit restriction agreement.

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Attovia Therapeutics, Inc. (ATTO)	United States	$0.828B
4D Molecular Therapeutics, Inc. (FDMT)	United States	$0.733B	-4.10
Candel Therapeutics, Inc. (CADL)	United States	$0.885B	-8.86
Sana Biotechnology, Inc. (SANA)	United States	$0.886B	-4.92
Odyssey Therapeutics, Inc. (ODTX)	United States	$0.960B
Aura Biosciences, Inc. (AURA)	United States	$0.639B	-5.61
Cullinan Therapeutics, Inc. (CGEM)	United States	$0.993B	-5.72
Monte Rosa Therapeutics, Inc. (GLUE)	United States	$1.002B	-12.81
Allogene Therapeutics, Inc. (ALLO)	United States	$0.574B	-4.33
Prime Medicine, Inc. (PRME)	United States	$0.557B	-3.54